{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:54:09Z","timestamp":1790945649776,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00179-6","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:35:41Z","timestamp":1790937341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-525X","authenticated-orcid":false,"given":"Shih-Sung","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Che","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"179_CR1","unstructured":"Kumar S, Baughn, LB, Cowan, et al. Plasma cell myeloma\/multiple myeloma. In: WHO Classification of Haematolymphoid Tumours. 5th Edition (Board WCoTE, ed), 5th edn. Lyon, France: IARC Press, 2024: 625\u201330."},{"key":"179_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"179_CR3","first-page":"241","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"RW McKenna","year":"2017","unstructured":"McKenna RW, Kyle RA, Kuehl WM, Harris NL, Coupland RW, Fend F. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 241\u201358."},{"key":"179_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1309\/AJCPUS3PRRT5ZXVS","volume":"133","author":"A Heerema-McKenney","year":"2010","unstructured":"Heerema-McKenney A, Waldron J, Hughes S, et al. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. Am J Clin Pathol. 2010;133:265\u201370.","journal-title":"Am J Clin Pathol"},{"key":"179_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0002-9440(10)65022-5","volume":"156","author":"G Pruneri","year":"2000","unstructured":"Pruneri G, Fabris S, Baldini L, et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol. 2000;156:1505\u201313.","journal-title":"Am J Pathol"},{"key":"179_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood-2003-11-3837","volume":"104","author":"K Specht","year":"2004","unstructured":"Specht K, Haralambieva E, Bink K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood. 2004;104:1120\u20136.","journal-title":"Blood"},{"key":"179_CR7","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2016-01-689547","volume":"127","author":"B Kajal","year":"2016","unstructured":"Kajal B, Chang H. Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression. Blood. 2016;127:1619.","journal-title":"Blood"},{"key":"179_CR8","first-page":"192","volume":"30","author":"DA Hale","year":"2017","unstructured":"Hale DA, Krause JR. Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression, an uncommon variant. Proc (Bayl Univ Med Cent). 2017;30:192\u20134.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"179_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232674","volume":"12","author":"P Sharma","year":"2019","unstructured":"Sharma P, Sreedharanunni S, Sachdeva MUS, Malhotra P. \u201cMorphology can be misleading\u201d: small lymphocyte-like plasma cell myeloma. BMJ Case Rep. 2019;12:e232674.","journal-title":"BMJ Case Rep"},{"key":"179_CR10","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s00277-020-04322-w","volume":"100","author":"K Lee","year":"2021","unstructured":"Lee K, Ryu SW, Jang HR, Paik JH. Plasma cell myeloma with pure lymphocyte-like morphology. Ann Hematol. 2021;100:3071\u20133.","journal-title":"Ann Hematol"},{"key":"179_CR11","unstructured":"Montes-Moreno S, Geddie WR, Kersren MJ, et al. Lymphoplasmacytic lymphoma. In: WHO Classification of Haematolymphoid Tumours. 5th Edition (Board WCoTE, ed), 5th edn. Lyon, France: IARC Press, 2024: 394\u20138."},{"key":"179_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1309\/5EL22BH45PHUPM8P","volume":"127","author":"AC Seegmiller","year":"2007","unstructured":"Seegmiller AC, Xu Y, McKenna RW, Karandikar NJ. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol. 2007;127:176\u201381.","journal-title":"Am J Clin Pathol"},{"key":"179_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00428-015-1858-9","volume":"468","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468:259\u201375.","journal-title":"Virchows Arch"},{"key":"179_CR14","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","volume":"91","author":"PR Greipp","year":"1998","unstructured":"Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501\u20137.","journal-title":"Blood"},{"key":"179_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PAP.0000000000000253","volume":"27","author":"BJ Chen","year":"2020","unstructured":"Chen BJ, Chuang SS. Lymphoid neoplasms with plasmablastic differentiation: a comprehensive review and diagnostic approaches. Adv Anatomic Pathol. 2020;27:61\u201374.","journal-title":"Adv Anatomic Pathol"},{"key":"179_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/modpathol.3800355","volume":"18","author":"F Vega","year":"2005","unstructured":"Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806\u201315.","journal-title":"Mod Pathol"},{"key":"179_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1309\/27H8XJH31F3GUNAT","volume":"128","author":"ST Chang","year":"2007","unstructured":"Chang ST, Liao YL, Lu CL, Chuang SS, Li CY. Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol. 2007;128:339\u201344.","journal-title":"Am J Clin Pathol"},{"key":"179_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00428-022-03342-3","volume":"481","author":"BJ Chen","year":"2022","unstructured":"Chen BJ, Yuan CT, Yang CF, et al. Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. Virchows Arch. 2022;481:283\u201393.","journal-title":"Virchows Arch"},{"key":"179_CR19","first-page":"166","volume":"51","author":"K Foucar","year":"1983","unstructured":"Foucar K, Raber M, Foucar E, Barlogie B, Sandler CM, Alexanian R. Anaplastic myeloma with massive extramedullary involvement. Report of two cases Cancer. 1983;51:166\u201374.","journal-title":"Report of two cases Cancer"},{"key":"179_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3960\/jslrt.17035","volume":"58","author":"S Ichikawa","year":"2018","unstructured":"Ichikawa S, Fukuhara N, Hatta S, et al. Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission. J Clin Exp Hematop. 2018;58:39\u201342.","journal-title":"J Clin Exp Hematop"},{"key":"179_CR21","doi-asserted-by":"crossref","unstructured":"Wu J, Chu E, Chase CC, C et al. Anaplastic Multiple Myeloma: Case Series and Literature Review. Asploro J Biomed Clin Case Rep. 2022;5:1\u201311.","DOI":"10.36502\/2022\/ASJBCCR.6255"},{"key":"179_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/PAS.0000000000002140","volume":"48","author":"S Xiao","year":"2024","unstructured":"Xiao S, Lin Y, Fu J, et al. Epstein-Barr virus-positive plasma cell neoplasms in immunocompetent patients: a clinicopathological study of 15 cases from South China and literature review. Am J Surg Pathol. 2024;48:16\u201326.","journal-title":"Am J Surg Pathol"},{"key":"179_CR23","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/j.clml.2016.06.008","volume":"16","author":"N Ammannagari","year":"2016","unstructured":"Ammannagari N, Celotto K, Neppalli V, Lee K, Holstein SA. Anaplastic multiple myeloma: an aggressive variant with a poor response to novel therapies. Clin Lymphoma Myeloma Leuk. 2016;16:e129\u201331.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"179_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2024.04.011","author":"ST Chang","year":"2024","unstructured":"Chang ST, Wu HC, Kuo YT, Chuang SS. Multiple myeloma masquerades as T-cell lymphoma by nodal presentation with anaplastic morphology and expression of CD3 and CD45. Pathology (Phila). 2024. https:\/\/doi.org\/10.1016\/j.pathol.2024.04.011.","journal-title":"Pathology (Phila)"},{"key":"179_CR25","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blade","year":"2011","unstructured":"Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805\u201312.","journal-title":"J Clin Oncol"},{"key":"179_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jaad.2015.12.028","volume":"74","author":"J Malysz","year":"2016","unstructured":"Malysz J, Talamo G, Zhu J, et al. Cutaneous involvement in multiple myeloma (MM): a case series with clinicopathologic correlation. J Am Acad Dermatol. 2016;74:878\u201384.","journal-title":"J Am Acad Dermatol"},{"key":"179_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ajcp\/aqaa122","volume":"155","author":"G Panse","year":"2021","unstructured":"Panse G, Subtil A, McNiff JM, et al. Cutaneous involvement in plasma cell myeloma. Am J Clin Pathol. 2021;155:106\u201316.","journal-title":"Am J Clin Pathol"},{"key":"179_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade J, Beksac M, Caers J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"179_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clml.2022.12.002","volume":"23","author":"A Jurczyszyn","year":"2023","unstructured":"Jurczyszyn A, Olszewska-Szopa M, Vesole DH. The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2023;23:188\u201393.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"179_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3960\/jslrt.25029","volume":"65","author":"JY Jhuang","year":"2025","unstructured":"Jhuang JY, Hsieh YC, Kuo YT, Kang NW, Chuang SS. Initial disease presentation with myelomatous pleural effusion is an ominous sign for multiple myeloma: report of a case emphasizing cytological features and ancillary studies. J Clin Exp Hematop. 2025;65:185\u20138.","journal-title":"J Clin Exp Hematop"},{"key":"179_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s44313-025-00070-w","volume":"60","author":"BJ Chen","year":"2025","unstructured":"Chen BJ, Kuo YT, Chang ST, et al. Frequent association of malignant effusions in plasmablastic lymphoma: a single-institutional experience of nine cases in Taiwan. Blood Res. 2025;60:22.","journal-title":"Blood Res"},{"key":"179_CR32","doi-asserted-by":"crossref","unstructured":"Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Int Med. 1974;133:813\u20138.","DOI":"10.1001\/archinte.133.5.813"},{"key":"179_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fernandez de Larrea","year":"2021","unstructured":"Fernandez de Larrea C, Kyle R, Rosinol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11:192.","journal-title":"Blood Cancer J"},{"key":"179_CR34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek T, Bezdekova R, Zihala D, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol. 2023;41:1383\u201392.","journal-title":"J Clin Oncol"},{"key":"179_CR35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","volume":"13","author":"J Blade","year":"1999","unstructured":"Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259\u201372.","journal-title":"Hematol Oncol Clin North Am"},{"key":"179_CR36","first-page":"225","volume":"41","author":"U Atas","year":"2024","unstructured":"Atas U, Salim O, Iltar U, et al. Survival outcomes of patients with primary plasma cell leukemia in the era of proteasome inhibitors and immunomodulatory agents: a real-life multicenter analysis. Turk J Haematol. 2024;41:225\u201335.","journal-title":"Turk J Haematol"},{"key":"179_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/10428194.2018.1473574","volume":"60","author":"A Jurczyszyn","year":"2019","unstructured":"Jurczyszyn A, Castillo JJ, Avivi I, et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019;60:118\u201323.","journal-title":"Leuk Lymphoma"},{"key":"179_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1600-0609.1989.tb01493.x","volume":"51","author":"S Pileri","year":"1989","unstructured":"Pileri S, Poggi S, Baglioni P, et al. Histology and immunohistology of bone marrow biopsy in multiple myeloma. Eur J Haematol Suppl. 1989;51:52\u20139.","journal-title":"Eur J Haematol Suppl"},{"key":"179_CR39","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/sj.leu.2403823","volume":"19","author":"S Kumar","year":"2005","unstructured":"Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005;19:1466\u201370.","journal-title":"Leukemia"},{"key":"179_CR40","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","volume":"81","author":"H Harada","year":"1993","unstructured":"Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658\u201363.","journal-title":"Blood"},{"key":"179_CR41","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","volume":"12","author":"C Pellat-Deceunynck","year":"1998","unstructured":"Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977\u201382.","journal-title":"Leukemia"},{"key":"179_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","volume":"97","author":"AC Rawstron","year":"1997","unstructured":"Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46\u201355.","journal-title":"Br J Haematol"},{"key":"179_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/1096-8652(200008)64:4<311::AID-AJH13>3.0.CO;2-U","volume":"64","author":"N Sahara","year":"2000","unstructured":"Sahara N, Ihara M, Ono T, et al. Multiple myeloma expressing CD19(+)CD56(-) phenotype. Am J Hematol. 2000;64:311\u20133.","journal-title":"Am J Hematol"},{"key":"179_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.beha.2010.09.002","volume":"23","author":"S Kumar","year":"2010","unstructured":"Kumar S, Kimlinger T, Morice W. Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Practice & Research. 2010;23:433\u201351.","journal-title":"Best Practice & Research"},{"key":"179_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","volume":"13","author":"M Miettinen","year":"2005","unstructured":"Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205\u201320.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"179_CR46","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2141.1996.tb08993.x","volume":"95","author":"M Ocqueteau","year":"1996","unstructured":"Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol. 1996;95:489\u201393.","journal-title":"Br J Haematol"},{"key":"179_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/10428199809057558","volume":"30","author":"L Escribano","year":"1998","unstructured":"Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma. 1998;30:459\u201366.","journal-title":"Leuk Lymphoma"},{"key":"179_CR48","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.5858\/2003-127-1596-CBNLIP","volume":"127","author":"IB Bayer-Garner","year":"2003","unstructured":"Bayer-Garner IB, Schwartz MR, Lin P, Smoller BR. CD117, but not lysozyme, is positive in cutaneous plasmacytoma. Arch Pathol Lab Med. 2003;127:1596\u20138.","journal-title":"Arch Pathol Lab Med"},{"key":"179_CR49","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00428-003-0934-8","volume":"444","author":"A Lugli","year":"2004","unstructured":"Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S. Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch. 2004;444:264\u20138.","journal-title":"Virchows Arch"},{"key":"179_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/his.13196","volume":"71","author":"E Marks","year":"2017","unstructured":"Marks E, Shi Y, Wang Y. CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma. Histopathology. 2017;71:81\u20138.","journal-title":"Histopathology"},{"key":"179_CR51","first-page":"236","volume":"41","author":"H Keski","year":"2024","unstructured":"Keski H, Merdan S, Zemheri IE. Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis. Turk J Haematol. 2024;41:236\u201345.","journal-title":"Turk J Haematol"},{"key":"179_CR52","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/modpathol.2017.177","volume":"31","author":"Z Pan","year":"2018","unstructured":"Pan Z, Chen M, Zhang Q, et al. CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. Mod Pathol. 2018;31:718\u201331.","journal-title":"Mod Pathol"},{"key":"179_CR53","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0025-6196(12)61350-0","volume":"69","author":"GJ Ruiz-Arguelles","year":"1994","unstructured":"Ruiz-Arguelles GJ, San Miguel JF. Cell surface markers in multiple myeloma. Mayo Clin Proc. 1994;69:684\u201390.","journal-title":"Mayo Clin Proc"},{"key":"179_CR54","doi-asserted-by":"publisher","first-page":"e2021043","DOI":"10.4084\/MJHID.2021.043","volume":"13","author":"DSA Soliman","year":"2021","unstructured":"Soliman DSA, El Sabah H, Ganwo I, et al. Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: an aggressive disease with extramedullary involvement and very short survival. Mediterr J Hematol Infect Dis. 2021;13:e2021043.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"179_CR55","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/cup.14141","volume":"49","author":"P Li","year":"2022","unstructured":"Li P, Panse G, Singh S, Krivda SJ, McNiff JM. Cutaneous involvement by plasma cell myeloma with aberrant CD4 expression. J Cutan Pathol. 2022;49:921\u20134.","journal-title":"J Cutan Pathol"},{"key":"179_CR56","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jha2.935","volume":"5","author":"K Shiroshita","year":"2024","unstructured":"Shiroshita K, Kohashi S, Sakamoto M, Kudo H, Nakanishi K, Toyama T. Aberrant CD4 expression in plasmablastic transformation of multiple myeloma. EJHaem. 2024;5:629\u201330.","journal-title":"EJHaem"},{"key":"179_CR57","first-page":"927","volume":"10","author":"MA Vasef","year":"1997","unstructured":"Vasef MA, Medeiros LJ, Yospur LS, Sun NC, McCourty A, Brynes RK. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol. 1997;10:927\u201332.","journal-title":"Mod Pathol"},{"key":"179_CR58","doi-asserted-by":"crossref","unstructured":"Athanasiou E, Kaloutsi V, Kotoula V, et al. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol. 2001;116:535\u201342.","DOI":"10.1309\/BVT4-YP41-LCV2-5GT0"},{"key":"179_CR59","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735\u201341.","journal-title":"Blood"},{"key":"179_CR60","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1182\/blood.2023022018","volume":"142","author":"BE Luu","year":"2023","unstructured":"Luu BE, Xu SA. A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma. Blood. 2023;142:2034.","journal-title":"Blood"},{"key":"179_CR61","first-page":"2296809","volume":"29","author":"A AlZahrani","year":"2024","unstructured":"AlZahrani A, Alsuhebany N, Tailor IK, Alrajhi AM. Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects. Hematology (Amsterdam, Netherlands). 2024;29:2296809.","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"179_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2559.1989.tb02124.x","volume":"14","author":"AC Wotherspoon","year":"1989","unstructured":"Wotherspoon AC, Norton AJ, Isaacson PG. Immunoreactive cytokeratins in plasmacytomas. Histopathology. 1989;14:141\u201350.","journal-title":"Histopathology"},{"key":"179_CR63","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1177\/10668969221113490","volume":"31","author":"IH Penzhorn","year":"2023","unstructured":"Penzhorn IH, Schneider JW, Sher-Locketz C. The prevalence of Epstein-Barr virus in plasma cell neoplasms is higher in HIV-positive individuals. Int J Surg Pathol. 2023;31:564\u201371.","journal-title":"Int J Surg Pathol"},{"key":"179_CR64","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1097\/PAS.0000000000001923","volume":"46","author":"T Zhou","year":"2022","unstructured":"Zhou T, Cheng J, Karrs J, et al. Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma. Am J Surg Pathol. 2022;46:1364\u201379.","journal-title":"Am J Surg Pathol"},{"key":"179_CR65","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/jcp-2024-209513","volume":"77","author":"M Munoz de Toro","year":"2024","unstructured":"Munoz de Toro M, Fernandez-Pol S. Systematic literature review of published cases of reactive plasmacytosis in peripheral blood and bone marrow. J Clin Pathol. 2024;77:802\u20139.","journal-title":"J Clin Pathol"},{"key":"179_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00509","volume":"9","author":"K Sokol","year":"2019","unstructured":"Sokol K, Kartan S, Johnson WT, et al. Extreme peripheral blood plasmacytosis mimicking plasma cell leukemia as a presenting feature of angioimmunoblastic T-cell lymphoma (AITL). Front Oncol. 2019;9:509.","journal-title":"Front Oncol"},{"key":"179_CR67","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/pin.12854","volume":"69","author":"ST Pan","year":"2019","unstructured":"Pan ST, Wang RC, Kuo CC, Hsieh YC, Su YZ, Chuang SS. MYD88 L265P mutation analysis is a useful diagnostic adjunct for lymphoplasmacytic lymphoma with pleural effusion. Pathol Int. 2019;69:601\u20137.","journal-title":"Pathol Int"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00179-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:02:12Z","timestamp":1790942532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00179-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["179"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00179-6","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"61"}}